Quanterix Co. (NASDAQ:QTRX) Shares Sold by Cwm LLC

Cwm LLC decreased its stake in Quanterix Co. (NASDAQ:QTRX) by 5.1% during the 4th quarter, Holdings Channel reports. The firm owned 175,826 shares of the company’s stock after selling 9,512 shares during the quarter. Cwm LLC’s holdings in Quanterix were worth $4,807,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of QTRX. Lord Abbett & CO. LLC acquired a new stake in shares of Quanterix in the third quarter valued at about $27,744,000. Emerald Advisers LLC acquired a new position in Quanterix during the third quarter worth about $10,462,000. Invesco Ltd. boosted its position in Quanterix by 49.6% during the third quarter. Invesco Ltd. now owns 1,103,981 shares of the company’s stock worth $29,962,000 after acquiring an additional 366,117 shares during the last quarter. Emerald Mutual Fund Advisers Trust boosted its position in Quanterix by 353.4% during the third quarter. Emerald Mutual Fund Advisers Trust now owns 313,044 shares of the company’s stock worth $8,496,000 after acquiring an additional 243,994 shares during the last quarter. Finally, Mckinley Capital Management LLC acquired a new position in Quanterix during the third quarter worth about $2,215,000. Institutional investors and hedge funds own 86.48% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Scotiabank boosted their price target on shares of Quanterix from $30.00 to $32.00 and gave the stock a “sector outperform” rating in a research report on Monday, March 4th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Quanterix presently has a consensus rating of “Buy” and a consensus price target of $32.00.

Insider Activity

In other news, Director Laurie J. Olson sold 1,500 shares of the business’s stock in a transaction that occurred on Wednesday, February 14th. The shares were sold at an average price of $24.35, for a total value of $36,525.00. Following the sale, the director now directly owns 15,238 shares of the company’s stock, valued at approximately $371,045.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 8.20% of the company’s stock.

Quanterix Stock Down 1.2 %

Shares of QTRX stock opened at $16.10 on Wednesday. The firm’s 50-day moving average is $23.49 and its two-hundred day moving average is $23.58. Quanterix Co. has a 12 month low of $11.39 and a 12 month high of $29.70.

Quanterix (NASDAQ:QTRX) last issued its earnings results on Thursday, February 29th. The company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.05). Quanterix had a negative return on equity of 9.15% and a negative net margin of 26.42%. The firm had revenue of $31.55 million for the quarter, compared to analysts’ expectations of $27.92 million. As a group, equities analysts predict that Quanterix Co. will post -1.04 EPS for the current fiscal year.

Quanterix Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.